Patient-reported outcomes of brentuximab vedotin in Hodgkin lymphoma and anaplastic large-cell lymphoma

BACKGROUND: Patients with relapsed/refractory (R/R) Hodgkin lymphoma (HL) or R/R systemic anaplastic large-cell lymphoma (sALCL) treated with brentuximab vedotin (BV) experienced high remission rates in two Phase II trials. With increased response rates and survival times, patient-reported outcomes...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Onco Targets Ther
Asıl Yazarlar: Chen, Robert, Allibone, Suzanne, Bartlett, Nancy L, Brice, Pauline, Chen, Andy, Pose, Katrina, Rich, Lynn, Bonthapally, Vijay, Garfin, Phillip M, Fanale, Michelle
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Dove Medical Press 2016
Konular:
Original Research
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC4827881/
https://ncbi.nlm.nih.gov/pubmed/27103829
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/OTT.S96175
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller